From: Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice
Experiment | Controls | Treatment regimen | S. aureus strain | Bacterial dose (CFU/mouse) | Mice |
---|---|---|---|---|---|
Infected mice | Healthy mice | No treatment | LS-1 | 1 × 107 | NMRI N = 44, one experiment |
rAAV-IL2 | rAAV-LUC | 1010 vg at day −19 prior to bacterial inoculation | LS-1 | 5 × 107 | C57BL/6 N = 60, two experiments |
Adoptive transfer | PBS | 0.9 × 106 CD4+CD25+ cells at day −2 prior to bacterial inoculation | LS-1 | 5 × 107 | C57BL/6 N = 12, one experiment |
IL2 treatment | PBS | Daily injections, starting at day 3 post bacterial inoculation | LS-1 | 5 × 107 | C57BL/6 N = 18, two experiments |
Anti-CD25 antibody treatment | Rat IgG1 antibody | One injection at day −3 prior bacterial inoculation and at day 3 post bacterial inoculation | (1) LS-1 (2) Newman | (1) 3.5 × 107 (2) 6.5 × 106 | (1) C57BL/6 N = 20, one experiment (2) NMRI N = 28, one experiment |